NCT03676101View on ClinicalTrials.gov

Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

August 20, 2019

Study Completion Date

January 10, 2020

Conditions
Cervical CancersVulvar CancerVaginal CancerCIN1CIN2CIN 3AISInvasive CarcinomaMild Dysplasia of VulvaModerate Dysplasia of VulvaVin IIIVaIN1VaIN2VaIN3Genital Wart
Interventions
BIOLOGICAL

9-valent HPV Recombinant Vaccine

Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

BIOLOGICAL

Placebo

Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.

Trial Locations (1)

Unknown

Zhejiang Provincial Center for Disease Control and Prevention, Hanzhou

All Listed Sponsors
collaborator

Chongqing Bovax Biopharmaceutical Co., Ltd.

INDUSTRY

lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY

NCT03676101 - Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | Biotech Hunter | Biotech Hunter